JPS63218621A - 肥満症の予防・治療用組成物 - Google Patents
肥満症の予防・治療用組成物Info
- Publication number
- JPS63218621A JPS63218621A JP5387287A JP5387287A JPS63218621A JP S63218621 A JPS63218621 A JP S63218621A JP 5387287 A JP5387287 A JP 5387287A JP 5387287 A JP5387287 A JP 5387287A JP S63218621 A JPS63218621 A JP S63218621A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- obesity
- remedy
- prevention
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 208000008589 Obesity Diseases 0.000 title claims abstract description 12
- 235000020824 obesity Nutrition 0.000 title claims abstract description 12
- 230000002265 prevention Effects 0.000 title abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 6
- -1 alkali metal salt Chemical class 0.000 claims abstract description 6
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims abstract description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 238000007911 parenteral administration Methods 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract description 2
- 229960002429 proline Drugs 0.000 abstract description 2
- 159000000000 sodium salts Chemical class 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012050 conventional carrier Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002075 main ingredient Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- YMZJBJPWTXJQMR-LJUKVTEVSA-L Fosfomycin calcium Chemical compound [Ca+2].C[C@@H]1O[C@@H]1P([O-])([O-])=O YMZJBJPWTXJQMR-LJUKVTEVSA-L 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5387287A JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5387287A JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63218621A true JPS63218621A (ja) | 1988-09-12 |
| JPH0587048B2 JPH0587048B2 (enrdf_load_stackoverflow) | 1993-12-15 |
Family
ID=12954841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5387287A Granted JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63218621A (enrdf_load_stackoverflow) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207427B1 (en) | 1997-06-09 | 2001-03-27 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| WO2004083179A1 (ja) * | 2003-03-19 | 2004-09-30 | Kyowa Hakko Kogyo Co., Ltd. | 糖尿病治療剤 |
| WO2004085389A1 (ja) * | 2003-03-26 | 2004-10-07 | Kyowa Hakko Kogyo Co. Ltd. | 脂質代謝改善剤 |
| WO2004087657A1 (ja) * | 2003-03-28 | 2004-10-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗肥満剤 |
| WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
| WO2006131836A3 (en) * | 2005-03-22 | 2007-10-04 | Innodia Inc | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS504066A (enrdf_load_stackoverflow) * | 1972-11-23 | 1975-01-16 | ||
| JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
-
1987
- 1987-03-09 JP JP5387287A patent/JPS63218621A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS504066A (enrdf_load_stackoverflow) * | 1972-11-23 | 1975-01-16 | ||
| JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207427B1 (en) | 1997-06-09 | 2001-03-27 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| US6365381B2 (en) | 1997-06-09 | 2002-04-02 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| WO2004083179A1 (ja) * | 2003-03-19 | 2004-09-30 | Kyowa Hakko Kogyo Co., Ltd. | 糖尿病治療剤 |
| US7485662B2 (en) | 2003-03-19 | 2009-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for diabetes mellitus |
| WO2004085389A1 (ja) * | 2003-03-26 | 2004-10-07 | Kyowa Hakko Kogyo Co. Ltd. | 脂質代謝改善剤 |
| JPWO2004085389A1 (ja) * | 2003-03-26 | 2006-06-29 | 協和醗酵工業株式会社 | 脂質代謝改善剤 |
| WO2004087657A1 (ja) * | 2003-03-28 | 2004-10-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗肥満剤 |
| JPWO2004087657A1 (ja) * | 2003-03-28 | 2006-06-29 | 協和醗酵工業株式会社 | 抗肥満剤 |
| CN100351232C (zh) * | 2003-03-28 | 2007-11-28 | 协和发酵工业株式会社 | 抗肥胖剂 |
| WO2006131836A3 (en) * | 2005-03-22 | 2007-10-04 | Innodia Inc | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0587048B2 (enrdf_load_stackoverflow) | 1993-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2283108C2 (ru) | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| EP2992881B1 (en) | Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells | |
| JP2016028069A (ja) | 脂肪異栄養症の処置 | |
| US10596224B2 (en) | Method of treating a wound, comprising the step of administering a composition including a substance P | |
| Cevey et al. | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease | |
| TWI248359B (en) | Food materials for metabolic bone diseases | |
| JPS63218621A (ja) | 肥満症の予防・治療用組成物 | |
| CA2080820C (fr) | Derives azoiques, compositions pharmaceutiques et desinfectantes les contenant et leurs utilisations | |
| JP2022166040A (ja) | 皮膚疾患の処置のためのｄｉｍの舌下又は頬側の投与 | |
| JP5048372B2 (ja) | 育毛促進剤 | |
| HUE031910T2 (en) | Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals | |
| JPS60120995A (ja) | 新規アミノ酸誘導体の製法 | |
| CN117085005A (zh) | 5-羟甲基-2-呋喃甲酸在制备促血管生成相关产品中的应用 | |
| JP7364839B2 (ja) | 創傷治癒を促進する医薬品の製造におけるカンナフラビンａの使用 | |
| Zahid et al. | Effect of chloroquine on liver weight of developing albino rats | |
| KR101581508B1 (ko) | 코엔자임 ｑ１０을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물 | |
| CN109219451A (zh) | 包含多不饱和酮和叶酸配偶体的联合疗法 | |
| JP2004522783A (ja) | 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用 | |
| FR2605884A1 (fr) | Nouvelle association medicamenteuse | |
| JP2021519769A (ja) | 皮膚障壁機能異常の改善用組成物 | |
| EP0404660B1 (fr) | Utilisation de complexes glycoprotéines extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau et procédé de préparation | |
| EP3283066B1 (en) | 4-phenylbutyric acid derivatives | |
| EP0404661A2 (fr) | Utilisation de lipopolysaccharides extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau | |
| JPH02215725A (ja) | 抗高脂血症剤 | |
| WO1999027937A2 (fr) | Procede d'inhibition de la production cellulaire de cytokines |